Skip to main content

Molecular monitoring of chronic myeloid leukemia: principles and interlaboratory standardization

Annals of Hematology volume 94, pages 219–225 (2015)Cite this article

Abstract

Serial quantification of BCR-ABL1 messenger RNA (mRNA) is an important therapeutic indicator for patients with chronic myeloid leukemia, but historically, there has been substantial variation in results reported by different laboratories. To help improve the comparability of results, an international scale (IS) for BCR-ABL1 was proposed which is being implemented by testing laboratories worldwide. This is being achieved most commonly by the derivation of laboratory-specific conversion factors, but increasingly by the use of kits or reagents that are calibrated to the first World Health Organization International Genetic Reference Panel for quantitation of BCR-ABL1 mRNA. Recent attention has focused on the need to define and validate levels of deeper molecular response (MR) within the context of the IS. While there has been substantial progress in the alignment of results, BCR-ABL1 measurement is technically challenging and standardization is an ongoing process.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

43,34 €

Price includes VAT (Finland)
Tax calculation will be finalised during checkout.

Fig. 1
Fig. 2

References

  1. Sawyers CL, Timson L, Kawasaki ES, Clark SS, Witte ON, Champlin R (1990) Molecular relapse in chronic myelogenous leukemia patients after bone marrow transplantation detected by polymerase chain reaction. Proc Natl Acad Sci U S A 87(2):563–567

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  2. Gabert J, Thuret I, Lafage M, Carcassonne Y, Maraninchi D, Mannoni P (1989) Detection of residual bcr/abl translocation by polymerase chain reaction in chronic myeloid leukaemia patients after bone-marrow transplantation. Lancet 2(8672):1125–1128

    Article  CAS  PubMed  Google Scholar 

  3. Hughes TP, Goldman JM (1990) Biological importance of residual leukaemic cells after BMT for CML: does the polymerase chain reaction help? Bone Marrow Transplant 5(1):3–6

    CAS  PubMed  Google Scholar 

  4. Cross NC, Hughes TP, Feng L, O’Shea P, Bungey J, Marks DI, Ferrant A, Martiat P, Goldman JM (1993) Minimal residual disease after allogeneic bone marrow transplantation for chronic myeloid leukaemia in first chronic phase: correlations with acute graft-versus-host disease and relapse. Br J Haematol 84(1):67–74

    Article  CAS  PubMed  Google Scholar 

  5. Cross NC (2009) Standardisation of molecular monitoring for chronic myeloid leukaemia. Best Pract Res Clin Haematol 22(3):355–365. doi:10.1016/j.beha.2009.04.001

    Article  PubMed  Google Scholar 

  6. Hughes T, Janssen JW, Morgan G, Martiat P, Saglio G, Pignon JM, Pignatti FP, Mills K, Keating A, Gluckman E et al (1990) False-positive results with PCR to detect leukaemia-specific transcript. Lancet 335(8696):1037–1038

    Article  CAS  PubMed  Google Scholar 

  7. Cross NC, Feng L, Chase A, Bungey J, Hughes TP, Goldman JM (1993) Competitive polymerase chain reaction to estimate the number of BCR-ABL transcripts in chronic myeloid leukemia patients after bone marrow transplantation. Blood 82(6):1929–1936

    CAS  PubMed  Google Scholar 

  8. Lion T, Henn T, Gaiger A, Kalhs P, Gadner H (1993) Early detection of relapse after bone marrow transplantation in patients with chronic myelogenous leukaemia. Lancet 341(8840):275–276

    Article  CAS  PubMed  Google Scholar 

  9. Malinge MC, Mahon FX, Delfau MH, Daheron L, Kitzis A, Guilhot F, Tanzer J, Grandchamp B (1992) Quantitative determination of the hybrid Bcr-Abl RNA in patients with chronic myelogenous leukaemia under interferon therapy. Br J Haematol 82(4):701–707

    Article  CAS  PubMed  Google Scholar 

  10. Hochhaus A, Lin F, Reiter A, Skladny H, van Rhee F, Shepherd PC, Allan NC, Hehlmann R, Goldman JM, Cross NC (1995) Variable numbers of BCR-ABL transcripts persist in CML patients who achieve complete cytogenetic remission with interferon-alpha. Br J Haematol 91(1):126–131

    Article  CAS  PubMed  Google Scholar 

  11. Hochhaus A, Lin F, Reiter A, Skladny H, Mason PJ, van Rhee F, Shepherd PC, Allan NC, Hehlmann R, Goldman JM, Cross NC (1996) Quantification of residual disease in chronic myelogenous leukemia patients on interferon-alpha therapy by competitive polymerase chain reaction. Blood 87(4):1549–1555

    CAS  PubMed  Google Scholar 

  12. Lin F, Chase A, Bungey J, Goldman JM, Cross NC (1995) Correlation between the proportion of Philadelphia chromosome-positive metaphase cells and levels of BCR-ABL mRNA in chronic myeloid leukaemia. Genes Chromosom Cancer 13(2):110–114

    Article  CAS  PubMed  Google Scholar 

  13. Beillard E, Pallisgaard N, van der Velden VH, Bi W, Dee R, van der Schoot E, Delabesse E, Macintyre E, Gottardi E, Saglio G, Watzinger F, Lion T, van Dongen JJ, Hokland P, Gabert J (2003) Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using ‘real-time’ quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR)—a Europe against cancer program. Leukemia 17(12):2474–2486. doi:10.1038/sj.leu.2403136

    Article  CAS  PubMed  Google Scholar 

  14. Branford S, Hughes T (2006) Diagnosis and monitoring of chronic myeloid leukemia by qualitative and quantitative RT-PCR. Methods Mol Med 125:69–92

    CAS  PubMed  Google Scholar 

  15. Branford S, Cross NC, Hochhaus A, Radich J, Saglio G, Kaeda J, Goldman J, Hughes T (2006) Rationale for the recommendations for harmonizing current methodology for detecting BCR-ABL transcripts in patients with chronic myeloid leukaemia. Leukemia 20(11):1925–1930. doi:10.1038/sj.leu.2404388

    Article  CAS  PubMed  Google Scholar 

  16. Jennings LJ, Smith FA, Halling KC, Persons DL, Kamel-Reid S, Molecular Oncology Resource Committee of the College of American P (2012) Design and analytic validation of BCR-ABL1 quantitative reverse transcription polymerase chain reaction assay for monitoring minimal residual disease. Arch Pathol Lab Med 136(1):33–40. doi:10.5858/arpa.2011-0136-OA

    Article  PubMed  Google Scholar 

  17. Gabert J, Beillard E, van der Velden VH, Bi W, Grimwade D, Pallisgaard N, Barbany G, Cazzaniga G, Cayuela JM, Cave H, Pane F, Aerts JL, De Micheli D, Thirion X, Pradel V, Gonzalez M, Viehmann S, Malec M, Saglio G, van Dongen JJ (2003) Standardization and quality control studies of ‘real-time’ quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia—a Europe Against Cancer program. Leukemia 17(12):2318–2357. doi:10.1038/sj.leu.2403135

    Article  CAS  PubMed  Google Scholar 

  18. Foroni L, Wilson G, Gerrard G, Mason J, Grimwade D, White HE, de Castro DG, Austin S, Awan A, Burt E, Clench T, Farruggia J, Hancock J, Irvine AE, Kizilors A, Langabeer S, Milner BJ, Nickless G, Schuh A, Sproul A, Wang L, Wickham C, Cross NC (2011) Guidelines for the measurement of BCR-ABL1 transcripts in chronic myeloid leukaemia. Br J Haematol 153(2):179–190. doi:10.1111/j.1365-2141.2011.08603.x

    Article  CAS  PubMed  Google Scholar 

  19. Hughes TP, Kaeda J, Branford S, Rudzki Z, Hochhaus A, Hensley ML, Gathmann I, Bolton AE, van Hoomissen IC, Goldman JM, Radich JP, International Randomised Study of Interferon versus STISG (2003) Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med 349(15):1423–1432. doi:10.1056/NEJMoa030513

    Article  CAS  PubMed  Google Scholar 

  20. Hughes T, Deininger M, Hochhaus A, Branford S, Radich J, Kaeda J, Baccarani M, Cortes J, Cross NC, Druker BJ, Gabert J, Grimwade D, Hehlmann R, Kamel-Reid S, Lipton JH, Longtine J, Martinelli G, Saglio G, Soverini S, Stock W, Goldman JM (2006) Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood 108(1):28–37. doi:10.1182/blood-2006-01-0092

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  21. Lauseker M, Hanfstein B, Haferlach C, Schnittger S, Pfirrmann M, Fabarius A, Schlegelberger B, Saussele S, Dietz CT, Erben P, Hehlmann R, Hasford J, Hochhaus A, Muller MC (2014) Equivalence of BCR-ABL transcript levels with complete cytogenetic remission in patients with chronic myeloid leukemia in chronic phase. J Cancer Res Clin Oncol. doi:10.1007/s00432-014-1746-8

    PubMed  Google Scholar 

  22. Cross NC, White HE, Muller MC, Saglio G, Hochhaus A (2012) Standardized definitions of molecular response in chronic myeloid leukemia. Leukemia 26(10):2172–2175. doi:10.1038/leu.2012.104

    Article  CAS  PubMed  Google Scholar 

  23. Baccarani M, Deininger MW, Rosti G, Hochhaus A, Soverini S, Apperley JF, Cervantes F, Clark RE, Cortes JE, Guilhot F, Hjorth-Hansen H, Hughes TP, Kantarjian HM, Kim DW, Larson RA, Lipton JH, Mahon FX, Martinelli G, Mayer J, Muller MC, Niederwieser D, Pane F, Radich JP, Rousselot P, Saglio G, Saussele S, Schiffer C, Silver R, Simonsson B, Steegmann JL, Goldman JM, Hehlmann R (2013) European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood 122(6):872–884. doi:10.1182/blood-2013-05-501569

    Article  CAS  PubMed  Google Scholar 

  24. Cross NCP, White H, Colomer D, Ehrencrona H, Foroni L, Gottardi E, Lange T, Lion T, Polakova KM, Dulucq S, Martinelli G, Leibundgut EO, Pallisgaard N, Barbany G, Sacha T, Talmaci R, Izzo B, Saglio G, Pane F, Müller MC et al. (2015) reference:Laboratory recommendations for scoring deep molecular responses following treatment for chronic myeloid leukemia. Leukemia. doi:10.1038/leu.2015.29

  25. Branford S, Fletcher L, Cross NC, Muller MC, Hochhaus A, Kim DW, Radich JP, Saglio G, Pane F, Kamel-Reid S, Wang YL, Press RD, Lynch K, Rudzki Z, Goldman JM, Hughes T (2008) Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials. Blood 112(8):3330–3338. doi:10.1182/blood-2008-04-150680

    Article  CAS  PubMed  Google Scholar 

  26. Muller MC, Cross NC, Erben P, Schenk T, Hanfstein B, Ernst T, Hehlmann R, Branford S, Saglio G, Hochhaus A (2009) Harmonization of molecular monitoring of CML therapy in Europe. Leukemia 23(11):1957–1963. doi:10.1038/leu.2009.168

    Article  CAS  PubMed  Google Scholar 

  27. White HE, Matejtschuk P, Rigsby P, Gabert J, Lin F, Lynn Wang Y, Branford S, Muller MC, Beaufils N, Beillard E, Colomer D, Dvorakova D, Ehrencrona H, Goh HG, El Housni H, Jones D, Kairisto V, Kamel-Reid S, Kim DW, Langabeer S, Ma ES, Press RD, Romeo G, Wang L, Zoi K, Hughes T, Saglio G, Hochhaus A, Goldman JM, Metcalfe P, Cross NC (2010) Establishment of the first World Health Organization International Genetic Reference Panel for quantitation of BCR-ABL mRNA. Blood 116(22):e111–e117. doi:10.1182/blood-2010-06-291641

    Article  CAS  PubMed  Google Scholar 

  28. White HE, Hedges J, Bendit I, Branford S, Colomer D, Hochhaus A, Hughes T, Kamel-Reid S, Kim DW, Modur V, Muller MC, Pagnano KB, Pane F, Radich J, Cross NC, Labourier E (2013) Establishment and validation of analytical reference panels for the standardization of quantitative BCR-ABL1 measurements on the international scale. Clin Chem 59(6):938–948. doi:10.1373/clinchem.2012.196477

    Article  CAS  PubMed  Google Scholar 

  29. Cayuela JM, Macintyre E, Darlington M, Abdelali RB, Fund X, Villarese P, Tulliez M, Raffoux E, Sigaux F, Rea D, Seror V (2011) Cartridge-based automated BCR-ABL1 mRNA quantification: solving the issues of standardization, at what cost? Haematologica 96(5):664–671. doi:10.3324/haematol.2010.034389

    Article  PubMed Central  PubMed  Google Scholar 

  30. Maute C, Nibourel O, Rea D, Coiteux V, Grardel N, Preudhomme C, Cayuela JM, on behalf of G (2014) Calibration of BCR-ABL1 mRNA quantification methods using genetic reference materials is a valid strategy to report results on the international scale. Clin Biochem. doi:10.1016/j.clinbiochem.2014.05.067

    PubMed  Google Scholar 

  31. White H, Deprez L, Corbisier P, Hall V, Lin F, Mazoua S, Trapmann S, Aggerholm A, Andrikovics H, Akiki S, Barbany G, Boeckx N, Bench A, Catherwood M, Cayuela JM, Chudleigh S, Clench T, Colomer D, Daraio F, Dulucq S, Farrugia J, Fletcher L, Foroni L, Ganderton R, Gerrard G, Gineikiene E, Hayette S, El Housni H, Izzo B, Jansson M, Johnels P, Jurcek T, Kairisto V, Kizilors A, Kim DW, Lange T, Lion T, Polakova KM, Martinelli G, McCarron S, Merle PA, Milner B, Mitterbauer-Hohendanner G, Nagar M, Nickless G, Nomdedeu J, Nymoen DA, Leibundgut EO, Ozbek U, Pajic T, Pfeifer H, Preudhomme C, Raudsepp K, Romeo G, Sacha T, Talmaci R, Touloumenidou T, Van der Velden VH, Waits P, Wang L, Wilkinson E, Wilson G, Wren D, Zadro R, Ziermann J, Zoi K, Muller MC, Hochhaus A, Schimmel H, Cross NC, Emons H (2015) A certified plasmid reference material for the standardisation of BCR-ABL1 mRNA quantification by real time quantitative PCR. Leukemia 29(2):369–376. doi:10.1038/leu.2014.217

  32. Soverini S, Hochhaus A, Nicolini FE, Gruber F, Lange T, Saglio G, Pane F, Muller MC, Ernst T, Rosti G, Porkka K, Baccarani M, Cross NC, Martinelli G (2011) BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet. Blood 118(5):1208–1215. doi:10.1182/blood-2010-12-326405

    Article  CAS  PubMed  Google Scholar 

  33. Ross DM, Branford S, Seymour JF, Schwarer AP, Arthur C, Bartley PA, Slader C, Field C, Dang P, Filshie RJ, Mills AK, Grigg AP, Melo JV, Hughes TP (2010) Patients with chronic myeloid leukemia who maintain a complete molecular response after stopping imatinib treatment have evidence of persistent leukemia by DNA PCR. Leukemia 24(10):1719–1724. doi:10.1038/leu.2010.185

    Article  CAS  PubMed  Google Scholar 

  34. Bartley PA, Ross DM, Latham S, Martin-Harris MH, Budgen B, Wilczek V, Branford S, Hughes TP, Morley AA (2010) Sensitive detection and quantification of minimal residual disease in chronic myeloid leukaemia using nested quantitative PCR for BCR-ABL DNA. Int J Lab Hematol 32(6 Pt 1):e222–e228. doi:10.1111/j.1751-553X.2010.01236.x

    Article  CAS  PubMed  Google Scholar 

  35. Sobrinho-Simoes M, Wilczek V, Score J, Cross NC, Apperley JF, Melo JV (2010) In search of the original leukemic clone in chronic myeloid leukemia patients in complete molecular remission after stem cell transplantation or imatinib. Blood 116(8):1329–1335. doi:10.1182/blood-2009-11-255109

    Article  CAS  PubMed  Google Scholar 

  36. Goh HG, Lin M, Fukushima T, Saglio G, Kim D, Choi SY, Kim SH, Lee J, Lee YS, Oh SM, Kim DW (2011) Sensitive quantitation of minimal residual disease in chronic myeloid leukemia using nanofluidic digital polymerase chain reaction assay. Leuk Lymphoma 52(5):896–904. doi:10.3109/10428194.2011.555569

    Article  CAS  PubMed  Google Scholar 

  37. Jennings LJ, George D, Czech J, Yu M, Joseph L (2014) Detection and quantification of BCR-ABL1 fusion transcripts by droplet digital PCR. J Mol Diagn 16(2):174–179. doi:10.1016/j.jmoldx.2013.10.007

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

All the three authors received research support from the European LeukemiaNet via the “European Treatment and Outcome Study” (EUTOS).

Conflict of interest

The authors declare that they have no relevant conflict of interest.

Author information

Affiliations

  1. Faculty of Medicine, University of Southampton, Southampton, UK

    Nicholas C. P. Cross

  2. Wessex Regional Genetics Laboratory, Salisbury District Hospital, Salisbury, SP2 8BJ, UK

    Nicholas C. P. Cross

  3. Abteilung Hämatologie/Onkologie, Klinik für Innere Medizin II, Universitätsklinikum Jena, Jena, Germany

    Andreas Hochhaus

  4. III. Medizinische Klinik, Universitätsmedizin Mannheim, Mannheim, Germany

    Martin C. Müller

Authors
  1. Nicholas C. P. Cross
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Andreas Hochhaus
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Martin C. Müller
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Nicholas C. P. Cross.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Cross, N.C.P., Hochhaus, A. & Müller, M.C. Molecular monitoring of chronic myeloid leukemia: principles and interlaboratory standardization. Ann Hematol 94, 219–225 (2015). https://doi.org/10.1007/s00277-015-2315-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00277-015-2315-1

Keywords

  • Chronic myeloid leukemia
  • BCR-ABL1 mRNA
  • BCR-ABL1 measurement